132 related articles for article (PubMed ID: 37370819)
21. Development and external validation of prognostic nomograms for liver disease-free and overall survival in locally advanced rectal cancer with neoadjuvant therapy: a post cohort study based on the FOWARC trial.
Zhou J; Li T; Xiao Y; Lin J; Chen X; Peng S; Huang M; Shi X; Cai L; Huang P; Huang M
Ann Transl Med; 2022 Jun; 10(12):694. PubMed ID: 35845530
[TBL] [Abstract][Full Text] [Related]
22. Locally advanced rectal cancer: a multivariate analysis of outcome risk factors.
Bufalari A; Boselli C; Giustozzi G; Moggi L
J Surg Oncol; 2000 May; 74(1):2-10. PubMed ID: 10861600
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of mesorectal package area in patients with locally advanced rectal cancer following neoadjuvant chemoradiotherapy: A retrospective cohort study.
Guan B; Huang X; Xia H; Guan G; Xu B
Front Oncol; 2022; 12():941786. PubMed ID: 36263216
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
25. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
[TBL] [Abstract][Full Text] [Related]
26. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
27. Impact of Total Neoadjuvant Therapy vs. Standard Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis of Randomized Trials.
Riesco-Martinez MC; Fernandez-Martos C; Gravalos-Castro C; Espinosa-Olarte P; La Salvia A; Robles-Diaz L; Modrego-Sanchez A; Garcia-Carbonero R
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33291454
[TBL] [Abstract][Full Text] [Related]
28. FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer.
Lovinfosse P; Polus M; Van Daele D; Martinive P; Daenen F; Hatt M; Visvikis D; Koopmansch B; Lambert F; Coimbra C; Seidel L; Albert A; Delvenne P; Hustinx R
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):365-375. PubMed ID: 29046927
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Locally Advanced Rectal Cancer Patients Treated with Total Neoadjuvant Treatment: A Meta-Anaysis of Randomized Controlled Trials.
Gabbani M; Giorgi C; Napoli G; Tebano U; Perrone MS; Missiroli S; Berretta M; Mandarà M; Zaninelli M; Luca N; Grigolato D; Muraro M; Rinaldi G; Pinton P; Fiorica F
Clin Colorectal Cancer; 2022 Dec; 21(4):297-308. PubMed ID: 36210320
[TBL] [Abstract][Full Text] [Related]
30. Comparing outcomes following total neoadjuvant therapy and following neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer.
Zhu S; Brodin NP; English K; Ohri N; Chuy JW; Rajdev LN; Narang R; Kalnicki S; Guha C; Garg MK; Kabarriti R
EClinicalMedicine; 2019 Nov; 16():23-29. PubMed ID: 31832617
[TBL] [Abstract][Full Text] [Related]
31. Timing to achieve the best recurrence-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: experience in a large-volume center in China.
Wang X; Zheng Z; Zhu H; Yu Q; Huang S; Lu X; Huang Y; Chi P
Int J Colorectal Dis; 2021 May; 36(5):1007-1016. PubMed ID: 33398511
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment Inflammatory-Nutritional Biomarkers Predict Responses to Neoadjuvant Chemoradiotherapy and Survival in Locally Advanced Rectal Cancer.
Wang Y; Chen L; Zhang B; Song W; Zhou G; Xie L; Yu D
Front Oncol; 2021; 11():639909. PubMed ID: 33816284
[TBL] [Abstract][Full Text] [Related]
33. Is adjuvant chemotherapy necessary for locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery? A systematic review and meta-analysis.
Ma B; Ren Y; Chen Y; Lian B; Jiang P; Li Y; Shang Y; Meng Q
Int J Colorectal Dis; 2019 Jan; 34(1):113-121. PubMed ID: 30368569
[TBL] [Abstract][Full Text] [Related]
34. Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer - a Single Centre Study. (PPLB - 01).
Agrawal S; Banswal L; Saha A; Arun I; Datta SS; Chatterjee S; Ahmed R
Indian J Surg Oncol; 2016 Dec; 7(4):397-406. PubMed ID: 27872526
[TBL] [Abstract][Full Text] [Related]
35. The role of MRI after neochemoradiotherapy in predicting pathological tumor regression grade and clinical outcome in patients with locally advanced rectal adenocarcinoma.
Niu S; Chen Y; Peng F; Wen J; Xiong J; Yang Z; Peng J; Bao Y; Ding L
Front Oncol; 2023; 13():1118518. PubMed ID: 37377906
[TBL] [Abstract][Full Text] [Related]
36. Increased lymph node yield indicates improved survival in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Wang Y; Zhou M; Yang J; Sun X; Zou W; Zhang Z; Zhang J; Shen L; Yang L; Zhang Z
Cancer Med; 2019 Aug; 8(10):4615-4625. PubMed ID: 31250569
[TBL] [Abstract][Full Text] [Related]
37. Preoperative Fibrinogen-Albumin Ratio Index (FARI) is a Reliable Prognosis and Chemoradiotherapy Sensitivity Predictor in Locally Advanced Rectal Cancer Patients Undergoing Radical Surgery Following Neoadjuvant Chemoradiotherapy.
Lu S; Liu Z; Zhou X; Wang B; Li F; Ma Y; Wang W; Ma J; Wang Y; Wang H; Fu W
Cancer Manag Res; 2020; 12():8555-8568. PubMed ID: 32982448
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis.
Kong JC; Guerra GR; Warrier SK; Lynch AC; Michael M; Ngan SY; Phillips W; Ramsay G; Heriot AG
Colorectal Dis; 2018 Jul; 20(7):574-585. PubMed ID: 29582537
[TBL] [Abstract][Full Text] [Related]
39. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
40. Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection.
He F; Ju HQ; Ding Y; Jiang Z; Li Z; Huang B; Wang X; Zhao Y; Li Y; Qi B; Luo W; Zhang Z; Pei Q; Chen H; Liu S; Pang X; Zheng J; Wang J; Ajani JA; Wan XB
Br J Cancer; 2020 Oct; 123(8):1244-1252. PubMed ID: 32724220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
